Felix C. Ringshausen, Annette Sauer-Heilborn, Tina Büttner, Anna-Maria Dittrich, Nicolaus Schwerk, Fabio Ius, Lutz Nährlich, Tobias Welte, Mark Greer
European Respiratory Journal 2023 61: 2201402; DOI: 10.1183/13993003.01402-2022

Extract

Cystic fibrosis (CF) is an incurable, autosomal recessive multisystem disorder that is associated with multiple complications, in particular progressive lung disease, chronic pulmonary infections, respiratory failure and reduced life expectancy [1, 2]. In this regard, lung transplantation is an established treatment option for end-stage CF lung disease, aiming to improve both quality of life and survival [3].